Business Wire

Takeda Reports Strong First Quarter FY2019 Results and Raises Guidance for the Full Year

Share

Takeda Pharmaceutical Company Limited (TOKYO:4502)(NYSE:TAK):

Underlying Revenue declined -0.8% vs FY2018 Q1 pro-forma revenue1

  • Takeda’s 14 global brands, with an aggregate revenue of 270.2 billion yen posted strong year-over-year growth of +22%. This growth mostly offset the negative impact from intensified competition, phasing, and generic erosion.
  • Takeda’s 5 key business areas represent ~78% of revenues.
    • GI grew +8% spearheaded by ENTYVIO continuing to gain market share.
    • Plasma Derived Therapy (PDT) Immunology grew +2% driven by Albumin growth, with Immunoglobulin (IG) sales impacted by phasing of Intravenous Immunoglobulin (IVIG) shipments.

    • Rare Diseases declined -10% with rare hematology impacted by competition and price pressure, and strong uptake of TAKHZYRO not fully offsetting the decline of other Hereditary Angioedema (HAE) products due to the switch to TAKHZYRO and stocking in FY2018 Q1.

    • Oncology grew +8% driven by expansion of NINLARO.

    • Neuroscience grew +10% driven by the U.S. business under a new commercial structure.

Underlying Core Operating Profit Margin 32.4% for Q1

  • Reported Operating Profit declined 90.0% to 9.9 billion yen, largely impacted by one-time integration costs as well as non-cash purchase accounting expenses including unwinding of inventory step-up, and increased amortization of intangibles and impairment.
  • Underlying Core Operating Profit Margin for the current period was 32.4% reflecting synergy savings and continued OPEX discipline.

Achieved several important pipeline milestones in Q1

  • Currently 19 New Molecular Entity assets in Phase 2 & 3.
  • Advances in Cell and Gene Therapy platforms where CAR-T Cell Therapy from T-CiRA moves towards clinic and the integration of Adeno-Associated Virus-based (AAV-based) process development and manufacturing center in Austria.
  • ENTYVIO subcutaneous formulation achieved primary endpoint as maintenance therapy in Crohn’s disease.
  • Orexin 2 receptor agonist TAK-925 received Sakigake Designation in Japan for treatment of narcolepsy.

Disposing non-core assets to generate cash and focus the business

  • Net debt / adjusted EBITDA reduced from 4.7x at end of FY2018 to 4.4x as of June 2019, which does not include the $3.4 billion upfront cash payment received July 1, 2019 for the sale of XIIDRA to Novartis.
  • Sale of TACHOSIL remains on track to close in second half of calendar year.
  • Negotiations ongoing for further potential divestments.

Costa Saroukos, Chief Financial Officer, commented:

“Takeda had a very strong start to the year, delivering on our strategic priorities while successfully executing the integration of Shire. The combination of solid performance across our 14 global brands, continued OPEX discipline, and realization of cost synergies resulted in strong margins and cash flow. We are also making steady progress against our divestiture plan, with the completion of the XIIDRA sale on July 1st.
For the full year, Takeda has revised management guidance upward to reflect updated VELCADE assumptions and divestitures, and now anticipates delivering an Underlying Core Operating Profit margin in the mid-to-high twenties.
Takeda is relentlessly executing towards our cost synergy, de-leveraging, and margin targets. We remain on track to achieve our previously raised cost synergy target of $2 billion by the end of FY 2021, we are committed to achieving our 2x net debt / adjusted EBITDA target over the next three to five years, and our strong start to fiscal 2019 gives us great confidence towards realizing top-tier margins in the medium-term.”

Reported Results for Q1 (April - June) FY2019

(billion yen)

REPORTED

CORE

UNDERLYING i.

FY2019 Q1

VS. PRIOR YEAR

FY2019 Q1

VS. PRIOR YEAR

 

Revenue

849.1

+88.8%

849.1

+88.8%

-0.8% y-o-y ii.

(pro-forma)

Operating Profit

9.9

-90.0%

283.0 iii.

+142.3%

 

Margin

1.2%

-20.8pp

33.3%

+7.4pp

32.4%

Net Profit iv.

-20.7

N/M v.

198.4

+103.0%

 

EPS (JPY)

-13 yen

-113 yen

128 yen

+3 yen

124 yen

  1. Underlying Growth compares two periods (quarters or years) of financial results under a common basis and is used by management to assess the business. These financial results are calculated on a constant currency basis and excluding the impact of divestitures and other amounts that are unusual, non-recurring items or unrelated to our ongoing operations.
  2. Growth versus FY2018 Q1 pro-forma revenue. Pro forma adjustments to reflect amortization of intangible assets as if the acquisition of Shire had occurred at the beginning of FY2018, while removing non-recurring costs related to the acquisition such as transaction costs. The adjustments also include removal of impacts related to Shire's oncology business which was divested in August 2018.
  3. Core Operating Profit represents net profit adjusted to exclude income tax expenses, our share of profit or loss of investments accounted for using the equity method, finance expenses and income, other operating expenses and income, amortization and impairment losses on intangible assets associated with products and other items that management believes are unrelated to our core operations, such as purchase accounting effects and transaction related costs
  4. Attributable to the owners of the company.
  5. Not Meaningful

FY2019 Management Guidance: Upward revision to reflect changes to assumptions

  • Takeda no longer assumes any additional U.S. competitor for VELCADE within FY2019
  • Reflects divestitures of XIIDRA (closed July 1, 2019) and TACHOSIL (expected close CY2019 H2)

 

Previous Guidance
(May 14, 2019)

Revised Guidance
(July 31, 2019)

Underlying Revenue Growth vi.

Flat to slightly declining

Flat to slightly increasing

Underlying Core Operating Profit Margin

Mid-twenties %

Mid-to-high-twenties %

Underlying Core EPS

350 – 370 yen

360 – 380 yen

Annual Dividend per Share

180 yen

180 yen

vi. Constant Exchange Rate growth (applying FY2018 full year average foreign exchange rate). Compared to baseline of 3,300 billion JPY (rounded pro-forma April 2018 - March 2019 combined revenue of Legacy Takeda and Legacy Shire, converted at April 2018 - March 2019 average exchange rate of 111 JPY/USD; also adjusted to remove the revenue from divested assets such as Techpool, Multilab, and TACHOSIL from Legacy Takeda, and the oncology portfolio and XIIDRA from Legacy Shire)

FY2019 Reported Forecast: Increasing Earnings forecasts with Reported Revenue forecast unchanged

(billion yen)

Previous Forecast
(May 14, 2019)

Revised Forecast

(July 31, 2019)

change

growth versus FY2018

Revenue

3,300.0

3,300.0

-

+57.4%

Operating Profit

-193.0

-166.0

+14.0%

-

Net Profit

-383.0

-367.7

+4.0%

-

EPS

-246 yen

-236 yen

+4.2%

-

Core Operating Profit

883.0

910.0

+3.1%

+98.1%

Exchange Rate

(annual average)

1 US$=111 yen

1 euro=124 yen

1 US$=111 yen

1 euro=124 yen

 

 

For more details on Takeda's FY2019 1st quarter results and other financial information, please visit https://www.takeda.com/investors/reports/

About Takeda Pharmaceutical Company Limited

Takeda Pharmaceutical Company Limited (TOKYO:4502/NYSE:TAK) is a global, values-based, R&D-driven biopharmaceutical leader headquartered in Japan, committed to bringing Better Health and a Brighter Future to patients by translating science into highly-innovative medicines. Takeda focuses its R&D efforts on four therapeutic areas: Oncology, Gastroenterology (GI), Rare Diseases and Neuroscience. We also make targeted R&D investments in Plasma-Derived Therapies and Vaccines. We are focusing on developing highly innovative medicines that contribute to making a difference in people's lives by advancing the frontier of new treatment options and leveraging our enhanced collaborative R&D engine and capabilities to create a robust, modality-diverse pipeline. Our employees are committed to improving quality of life for patients and to working with our partners in health care in approximately 80 countries and regions.
For more information, visit https://www.takeda.com

Important Notice

For the purposes of this notice, “press release” means this document, any oral presentation, any question and answer session and any written or oral material discussed or distributed by Takeda Pharmaceutical Company Limited (“Takeda”) in connection herewith this press release. This press release (including any oral briefing and any question-and-answer in connection with it) is not intended to, and does not constitute, represent or form part of any offer, invitation or solicitation of any offer to purchase, otherwise acquire, subscribe for, exchange, sell or otherwise dispose of, any securities or the solicitation of any vote or approval in any jurisdiction. No shares or other securities are being offered to the public by means of this press release. No offering of securities shall be made in the United States except pursuant to registration under the U.S. Securities Act of 1933, as amended, or an exemption therefrom. This press release is being given (together with any further information which may be provided to the recipient) on the condition that it is for use by the recipient for information purposes only (and not for the evaluation of any investment, acquisition, disposal or any other transaction). Any failure to comply with these restrictions may constitute a violation of applicable securities laws.

The companies in which Takeda directly and indirectly owns investments are separate entities. In this press release, “Takeda” is sometimes used for convenience where references are made to Takeda and its subsidiaries in general. Likewise, the words “we”, “us” and “our” are also used to refer to subsidiaries in general or to those who work for them. These expressions are also used where no useful purpose is served by identifying the particular company or companies.

Forward-Looking Statements

This press release and any materials distributed in connection with this press release may contain forward-looking statements, beliefs or opinions regarding Takeda’s future business, future position and results of operations, including estimates, forecasts, targets and plans for Takeda. In particular, this press release contains forecasts and management estimates related to the financial and operational performance of Takeda. Without limitation, forward looking statements often include the words such as “targets”, “plans”, “believes”, “hopes”, “continues”, “expects”, “aims”, “intends”, “will”, “may”, “should”, “would”, “could” “anticipates”, “estimates”, “projects”, “forecasts” or words or terms of similar substance or the negative thereof. Any forward-looking statements in this document are based on the current assumptions and beliefs of Takeda in light of the information currently available to it. Such forward-looking statements do not represent any guarantee by Takeda or its management of future performance and involve known and unknown risks, uncertainties and other factors, including but not limited to: the economic circumstances surrounding Takeda’s business, including general economic conditions in Japan, the United States and worldwide; competitive pressures and developments; applicable laws and regulations; the success of or failure of product development programs; decisions of regulatory authorities and the timing thereof; changes in exchange rates; claims or concerns regarding the safety or efficacy of marketed products or products candidates; and post-merger integration with acquired companies, any of which may cause Takeda’s actual results, performance, achievements or financial position to be materially different from any future results, performance, achievements or financial position expressed or implied by such forward-looking statements. For more information on these and other factors which may affect Takeda’s results, performance, achievements, or financial position, see “Item 3. Key Information—D. Risk Factors” in Takeda’s most recent annual report on Form 20-F filed with the U.S. Securities and Exchange Commission, available on Takeda’s website at: https://www.takeda.com/investors/reports/sec-filings/ or at www.sec.gov. Neither Takeda nor its management gives any assurances that the expectations expressed in these forward-looking statements will turn out to be correct, and actual results, performance or achievements could materially differ from expectations. Persons receiving this press release should not place undue reliance on forward looking statements. Takeda undertakes no obligation to update any of the forward-looking statements contained in this press release or any other forward-looking statements it may make, except as required by law or stock exchange rule. Past performance is not an indicator of future results and the results of Takeda in this press release may not be indicative of, and are not an estimate, forecast or projection of Takeda’s future results.

Certain Non-IFRS Financial Measures

This press release includes certain non-IFRS financial measures and targets. Takeda's management evaluates results and makes operating and investment decisions using both IFRS and non-IFRS measures included in this press release. Non-IFRS results exclude certain income and cost items which are included in IFRS results. By including these non-IFRS measures, management intends to provide investors with additional information to further analyze Takeda's performance, core results and underlying trends. Non-IFRS results are not prepared in accordance with IFRS and non-IFRS information should be considered a supplement to, and not a substitute for, financial statements prepared in accordance with IFRS. Investors are encouraged to review the reconciliations of non-IFRS financial measures to their most directly comparable IFRS measures.

Reconciliation from reported revenue to underlying revenue growth presented in accordance with IFRS are included as an appendix to this document.

Further information on certain of Takeda’s Non-IFRS measures, including reconciliations to the most comparable measures presented under IFRS, is posted on Takeda’s investor relations website at https://www.takeda.com/investors/reports/quarterly-announcements/quarterly-announcements-2019/

Medical information

This press release contains information about products that may not be available in all countries, or may be available under different trademarks, for different indications, in different dosages, or in different strengths. Nothing contained herein should be considered a solicitation, promotion or advertisement for any prescription drugs including the ones under development.

Financial information

Takeda’s financial statements are prepared in accordance with International Financial Reporting Standards (“IFRS”).
The Shire acquisition closed on January 8, 2019, and our consolidated results for the fiscal year ended March 31, 2019 include Shire’s results from January 8, 2019 to March 31, 2019. References to “Legacy Takeda” businesses are to our businesses held prior to our acquisition of Shire. References to “Legacy Shire” businesses are to those businesses acquired through the Shire acquisition.
This press release includes certain pro forma information giving effect to the Shire acquisition as if it had occurred on April 1, 2018. This pro forma information has not been prepared in accordance with Article 11 of Regulation S-X. This pro forma information is presented for illustrative purposes and is based on certain assumptions and judgments based on information available to us as of the date hereof, which may not necessarily have been applicable if the Shire acquisition had actually happened as of April 1, 2018. Moreover, this pro forma information gives effect to certain transactions and other events which are not directly attributable to the Shire acquisition and/or which happened subsequently to the Shire acquisition, such as divestitures and the effects of the purchase price allocation for the Shire acquisition, and therefore may not accurately reflect the effect on our financial condition and results of operations if the Shire acquisition had actually been completed on April 1, 2018. Therefore, undue reliance should not be placed on the pro forma information included herein.


1 Growth versus FY2018 Q1 pro-forma revenue (3-month April-June 2018 combined revenue of Legacy Takeda and Legacy Shire, excluding oncology business). Please see the appendix for more details.

Contact information

Investor Relations
Takashi Okubo, +81-(0)3-3278-2306
takeda.ir.contact@takeda.com

Media Relations
Kazumi Kobayashi, +81 (0)3-3278-2095
kazumi.kobayashi@takeda.com

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Vertex Enhances Integrated Tax Solution for SAP® Ariba®4.6.2020 14:13:00 EESTPress release

Vertex, Inc., a leading provider of tax technology and services, announced enhancements to its solutions integration with SAP® Ariba® Buying and Invoicing, providing customers with timely, advanced tax insights within their procurement and supply chain processes. Vertex launched an SAP Ariba Tax API and the Vertex Indirect Tax for Procurement with SAP Ariba app extension in 2018, enabling companies to obtain tax calculations from within SAP Ariba Buying and Invoicing, while also supporting the requisition and invoice reconciliation phases of the tax process. This integration with SAP Ariba solutions helps calculate tax at the purchase requisition, invoice reconciliation and final tax determination phases, carrying tax from the purchase requisition to the purchase order. The integrated solution is now enhanced to distinguish between vendor charged, buyer payable, self-assessed and value-added reverse charge taxes, as well as multiple levels of jurisdictions. SAP Ariba solutions provide

Moody’s Analytics Tops 14 International Categories in FocusEconomics Analyst Forecast Awards4.6.2020 14:00:00 EESTPress release

Moody’s Analytics, a global provider of financial intelligence, ranks #1 in 14 international categories in the 2020 FocusEconomics Analyst Forecast Awards. These awards include #1 Best Overall Forecaster – Hong Kong, plus the top ranking in five other forecast categories across 12 countries. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200604005200/en/ #1 Best Overall Forecaster – Hong Kong #1 Interest Rate Forecaster – Austria #1 Interest Rate Forecaster – Italy #1 Interest Rate Forecaster – Portugal #1 Interest Rate Forecaster – Bahrain #1 Inflation Forecaster – Belgium #1 Inflation Forecaster – Malaysia #1 Current Account Forecaster – Brazil #1 Current Account Forecaster – Uruguay #1 Fiscal Balance Forecaster – Croatia #1 Fiscal Balance Forecaster – Peru #1 GDP Forecaster – Malaysia #1 GDP Forecaster – Slovenia #1 GDP Forecaster – Tunisia We also took second or third place in an additional 29 categories including: #2 Be

Temenos Recognized as the Only Global Power Seller in the 2020 Deal Survey, With More Than Double the New Named Deals of the Next Banking Platform4.6.2020 12:30:00 EESTPress release

Temenos (SIX: TEMN), the banking software company, has been listed as the industry’s only ‘Global Power Seller’ in Forrester’s prestigious Global Banking Platform Deals Survey 2020 with 30% increase in new named deals. Temenos landed more new global banking deals than any other provider in 2019, as stated in the Forrester report. Temenos was also named ‘Top Global Player’ in the survey, based on combined deals, which represent a vendor’s ability to enhance its market position and keep creating value for its existing customers. Forrester reconfirmed Temenos’ status as a ‘Top Global Player’ for the 8th consecutive year. This ranking recognizes platforms with over 150 combined deals (new names and extended deals with existing customers) in more than five regions. With 177 deals signed with new and existing customers, Temenos maintained its position at the forefront of the table. Temenos also retains its position as a ‘Global Power Seller’, the highest status in the vendor pyramid for new

Deenova Continues its Pharmacy Automation Market Expansion with 7 Robots Sales in France4.6.2020 12:03:00 EESTPress release

Deenova reported today that its recent market momentum in 2020 relentlessly extended to France, with 7 new robots contracts received by Deenova from Vinci Construction and the French Ministry of Economy and Finance, Groupe Hospitalier de Haute-Saône in Vesoul, and Adef Résidences Association Hopital Nord 92 Villeneuve-la-Garenne in the greater Paris area. Loïc Bessin, Managing Director of Deenova and Ecodex in France, stated: “I’m delighted to advance Deenova’s undeniable and dominant international expansion in 2020, this time in France, with our Deenova’s centralised unit-dose robots and related products and consumables. I’m very proud for our French team to continue Deenova’s unparalleled success in pioneering the pharmacy unit-dose traceability sector, already started in Italy, Malta, and the United Kingdom. Our corporate DNA ensures maximum traceability of medicines, total security of unit-doses, and greater consumption efficiency resulting in a significant reduction in pharmacy ex

WORTH Partnership Project: Organic Chairs, Fish Leather and Interactive Clothing4.6.2020 10:00:00 EESTPress release

Organic chairs that are “nourished” to reach desired shape, glassware derived from special waste, new alternative materials derived from fish to replace animal leather, illustrated children’s clothing that are enriched with new content through augmented reality and app interactions: Recycling, sustainability and the advanced use of technology attested that the mantra is always at the heart of creativity and innovative experiences by new generation European designers. All designers, under the Worth Partnership Project, an initiative financed by the European Union COSME programme, will be online from the 15th to 21st of June to showcase their projects and their concepts behind. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200604005050/en/ Worth Partnership Project_"Lucid", organic chair "nourished” to reach desired shape (Photo: WORTH Partnership Project) 7 video conferences for 7 topics in 7 days: to discover the Worth Part

ADVA launches industry’s first ePRC optical cesium clock solution4.6.2020 10:00:00 EESTPress release

ADVA (FSE: ADV) today launched the industry’s first ePRC optical cesium atomic clock solution, protecting synchronization networks from costly and dangerous interruptions to satellite signals. The Oscilloquartz OSA 3350 ePRC+ provides unprecedented stability and significantly longer lifetime compared to all other ePRC cesium clocks. It’s also the first cesium clock on the market with built-in SNMP support. This innovation in the design of atomic clocks comes at a critical time when GNSS outages caused by jamming and spoofing attacks are on the rise. Long GNSS disruptions can cause severe network outages and so the OSA 3350 ePRC+ offers vital backup for mission-critical infrastructures that depend on satellite-based timing, such as mobile networks and power utilities. The OSA 3350 ePRC+ also meets the stringent performance demands as well as the cost points needed for mobile networks transitioning to 5G. This press release features multimedia. View the full release here: https://www.bus

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom